Despite a newly signed $645 million commercialization deal with Neuraxpharm Group for multiple sclerosis drug Briumvi (ublituximab) in Europe, shares of TG Therapeutics Inc. (NASDAQ:TGTX) tanked by 49.3% on Aug. 1 due to a perceived miss in U.S. net sales for the anti-CD20 monoclonal antibody during its first full quarter on the U.S. market.

Investment in life sciences in the U.K. in 2022 was 47% lower than in 2021, new figures from the government show, a decline the British pharma industry believes is down to the high clawback rates imposed on drug manufacturers deterring global investors.

After 50 years of censorship, there is now growing pressure on EU policymakers to stand up and play a role in promoting the development of psychedelics as medicines and in preparing the ground to ensure equitable access once there are approved products.

European biotechnology firms engaged in the discovery and development of new therapeutics collectively raised $1.9 billion in equity funding during the second quarter (Q2) of the year. Despite the ongoing lack of an IPO market – particularly for European firms – the total is roughly comparable with historic norms, absent the pandemic-related boom years of 2020 and 2021. It represents the fourth highest total raised during the last six years.

Vesalius Biocapital Partners Sàrl has called a first close on its fourth fund at €95 million (US$103 million) and now is targeting a total of €150 million, with new investors to be accepted on a "rolling closing" basis until the final close in 2024.

Scientists in the U.K. have reacted with dismay to the announcement that the National Cancer Research Institute (NCRI) is to close, 22 years after it was set up to coordinate the efforts of industry, government research agencies and medical charities that sponsor and fund clinical trials.

Could a bioactive peptide secreted in the saliva of ticks offer a useful therapy for people who have experienced intracerebral hemorrhage (ICH)? That’s the question Bioxodes SA has set out to answer, and the company is about to move its first-in-class drug candidate, Ir-CPI, which has dual anti-thrombotic and anti-inflammatory effects, into a phase IIa trial in patients with ICH.

In a move that saw shares tumble by 26%, Biosenic SA has halted a phase IIb trial for its allogeneic stem cell therapy, Allob, after it failed to accelerate healing when given to patients two days after they sustained tibial fractures. The company plans to shift its focus to its late-stage arsenic trioxide candidate for chronic graft-vs.-host disease (GVHD).